Rankings
▼
Calendar
RXRX Q3 2023 Earnings — Recursion Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena
RXRX
Recursion Pharmaceuticals, Inc.
$2B
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$10M
-22.6% YoY
Gross Profit
-$775,000
-7.7% margin
Operating Income
-$100M
-985.4% margin
Net Income
-$93M
-920.8% margin
EPS (Diluted)
$-0.43
QoQ Revenue Growth
-8.3%
Cash Flow
Operating Cash Flow
-$73M
Free Cash Flow
-$74M
Stock-Based Comp.
$17M
Balance Sheet
Total Assets
$631M
Total Liabilities
$193M
Stockholders' Equity
$438M
Cash & Equivalents
$387M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$10M
$13M
-22.6%
Gross Profit
-$775,000
-$2M
+67.1%
Operating Income
-$100M
-$63M
-59.1%
Net Income
-$93M
-$60M
-53.9%
Revenue Segments
License and Service
$10M
96%
Grant
$431,000
4%
← FY 2023
All Quarters
Q4 2023 →